Learning Objectives EARLY VS DEFERRED ART The Case is Made Should EarlyStage Asymptomatic HIV Patients Receive ART The INSIGHT START Study The CD4 Cell Count As a Measure of Immune Deficiency in HIV Patients ID: 736828
Download Presentation The PPT/PDF document "HIV 2015-2016: New Agents, New Strategie..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
HIV 2015-2016:New Agents, New StrategiesSlide2Slide3Slide4
Learning ObjectivesSlide5
EARLY VS DEFERRED ARTThe Case is MadeSlide6
Should Early-Stage Asymptomatic HIV Patients Receive ART? The INSIGHT START StudySlide7
The CD4+ Cell Count As a Measure of Immune Deficiency in HIV+ PatientsHow Good Is It?Slide8
Immediate vs Deferred ART and Isoniazid Preventive TherapyTEMPRANO Study
aSlide9
Global Agreement on EARLY ART InitiationSlide10Slide11
INSTIs vs Boosted PIs ACTG 5257 StudySlide12
The Triumph of INSTIs Over Boosted PIsACTG 5257 StudySlide13
INSTI vs Boosted PISINGLE Study (N=833)Slide14
Dolutegravir Superior to Boosted Darunavir FLAMINGO Study (N=484)Slide15
INSTIs vs Boosted PIs in Treatment-Naïve PatientsSummary of Clinical Evidence Slide16Slide17
Interesting But…Limitations of PADDLESlide18
New Formulation of TenofovirTAFSlide19
TAF Replaces TDF in Fixed-Dose Pill Slide20
Switching Virologically-Suppressed Patients From TDF- to TAF-Based RegimenImproved Virologic Outcomes at 48 Wk (N=1433)Slide21
Significant Improvement in BMD and Renal Function With Switch to TAFSlide22
Switching From TDF to TAF Improves Renal Function at 48 Wk in Patients With Renal Impairment Slide23
Fixed-Dose Tablet: DTG/ABC/3TCSTRIIVING StudySlide24
Virologic Outcomes Maintained in Patients Switched to DTG/ABC/3TC
STRIIVING StudySlide25
Possible Reasons for Discontinuations in STRIIVING Study Slide26Slide27
Dolutegravir MonotherapySwitch Study Suggests Benefit for Select PatientsSlide28
Dolutegravir Monotherapy Proceed With CautionSlide29
EFFICACY OF ART IN HIV-INFECTED WOMENSlide30
First All-Women Study of ART Efficacy WAVES StudySlide31
WAVES 48-Week Data Slide32
Why Did Results Differ From a Similar Study of Mostly Mena? Slide33
Why Is It Difficult to Recruit Women Into Clinical Trials?Slide34Slide35
Daclatasvir/Sofosbuvir for 8 vs 12 Wk to Treat HCV in HIV/HCV-Coinfected PatientsALLY-2 StudySlide36
Efficacy of Treating HCV With Ledipasvir/ Sofosbuvir for 12 Wk in HIV/HCV-Coinfected PatientsION-4 Study Slide37
New Combination of Sofosbuvir/ Velpatasvir Achieves High HCV SVR Rates Across HCV GenotypesASTRAL-1 StudySlide38
Grazoprevir/Elbasvir: High HCV Cure Rates in HIV/HCV-Coinfected PatientsC-EDGE CO-INFECTIONSlide39
Treatment of HIV/HCV CoinfectionLooking ForwardSlide40
LONG-ACTING FORMULATIONS Slide41
Switch To a Long-Acting Nanoparticle Emulsion Formulation of Cabotegravir + Rilpivirine: 32-Wk ResultsLATTE-2 Studya,b Slide42
Potential Benefits of Long-Acting Injectable AgentsSlide43
SummarySlide44
AbbreviationsSlide45
Abbreviations (cont)Slide46
Abbreviations (cont)Slide47
Abbreviations (cont)